Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized viral vector-based cancer vaccines targeting neoantigens, has announced the completion of its oversubscribed Series C equity financing raising €67.5 million ($72 million) from a syndicate of renowned
Tags :Karina Tschon
Vischer acted as legal advisor to LimmaTech Biologics as it successfully concluded a USD 37 million (CHF 33 million) Series A financing round, co-led by Adjuvant Capital, AXA IM Alts, and the Novo Holdings REPAIR Impact Fund.
Pierre Fabre Laboratories, the French pharmaceutical and dermo-cosmetic company, announced the acquisition of Vertical Bio, a a biotechnology company developing a novel antibody to treat certain forms of cancer. Vertical Bio was founded by Versant
Walder Wyss advises Swiss biotech Alentis Therapeutics in connection with their USD 105m Series C funding to support the development of its lead assets. The funding round was led by Jeito Capital together with Novo
A group of entrepreneurs advised by Nachfolgepartner have acquired all shares in iPet.ch, the largest online shop for pet food and accessories in Switzerland run by veterinarians. With a wide selection of high-quality products
Walder Wyss has advised BC Platforms, an expert of data science solutions for personalized healthcare, drug discovery and life science research, in connection with the CHF 20 million (approx. USD 20 million) growth financing round. This growth
The Swiss pharmaceutical BioVersys has raised CHF 24.2 million in a first closing of its Series C round. This first closing was significantly oversubscribed by both existing and new investors from diverse geographies. The company intends
ImmunOs Therapeutics has closed an oversubscribed Series B financing round totaling USD 74 million. The round was led by new investors Samsara BioCapital, Lightspeed Venture Partners, and Gimv, and joined by new investors Mission BioCapital, GL
Swiss biotech company, Engimmune Therapeutics completes its seed financing round raising CHF 15.5 million, co-led by Pureos Bioventures and Novo Holdings with incubation from BaseLaunch. Engimmune Therapeutics is a platform company using cutting-edge technologies
Private equity firm Astrog has entered into a binding agreement with privately owned industrial group International Chemical Investors Group (“ICIG”) whereby Astorg will acquire CordenPharma, a global pharmaceutical CDMO (Contract Development & Manufacturing Organisation) with
